ArticleFrontiers in neurology2021

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes.

Jean Schoenen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.